Second Generation Antipsychotics and Cardiovascular Adverse Effects: Developing Evidence-Based Recommendations for Primary Care Medicine.

Background: Second-generation antipsychotic medications (SGAs) are often used by primary care physicians (PCPs) to treat multiple psychiatric diagnoses. SGAs have been connected to a number of adverse effects, including cardiovascular disease. Currently, there are no published evidence-based recommendations addressing SGAs and cardiotoxicity that are directed toward PCPs.

Growth inhibition and toxicity assessments of cis-3,4-diaryl-α-methylene-γ-butyrolactams in cultured human renal cancer cells and zebrafish embryos.

This study aimed to compare and evaluate the growth inhibition effects of eight previously synthesized compounds, cis-3,4-diaryl-α-methylene-γ-butyrolactams (compounds 1-8), on two human renal carcinoma cell (RCC) lines: CRL-1932 (rapid growth) and HTB-44 (slow growth). MTT assays and flow cytometry were conducted, revealing that compounds 5 and 6 had the potential to induce cell death in the slow-growing RCC cells (HTB-44), while compound 8 demonstrated effectiveness in both RCC lines (HTB-44 and CRL-1932). Additionally, a non-transformed HEK293 cell line and a transgenic zebrafish with a green fluorescent kidney Tg(wt1b:egfp) were used to assess the toxicities of compounds 5, 6, and 8.

Biomarkers.

Background: Plasma biomarkers have recently emerged to detect symptomatic Alzheimer Disease (AD), but have yet to be validated in preclinical AD populations, where Aβ accumulates in the brain but older adults are cognitively unimpaired (CU). In addition to AD pathologic plasma biomarkers (amyloid and tau), inflammatory markers can accurately detect symptomatic AD. We used pathologic and inflammatory plasma biomarkers to predict amyloid PET status in CU older adults.